Success Metrics

Clinical Success Rate
100.0%

Based on 7 completed trials

Completion Rate
100%(7/7)
Active Trials
0(0%)
Results Posted
43%(3 trials)

Phase Distribution

Ph phase_1
3
33%
Ph phase_2
6
67%

Phase Distribution

3

Early Stage

6

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
3(33.3%)
Phase 2Efficacy & side effects
6(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

7 of 7 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(7)
Other(2)

Detailed Status

Completed7
unknown2

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (33.3%)
Phase 26 (66.7%)

Trials by Status

unknown222%
completed778%

Recent Activity

0 active trials
Showing 5 of 9
completedphase_1

3BNC117 and 10-1074 in ART-treated Individuals

NCT03526848
completedphase_2

Early Administration of Romidepsin and 3BNC117 in Treatment-naïve HIV Patients Starting ART

NCT03041012
completedphase_2

Romidepsin Plus 3BNC117 Phase 2a Study

NCT02850016
unknownphase_2

Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects

NCT03719664
completedphase_2

A Study of the Safety and Antiretroviral Activity of 3BNC117

NCT02588586
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT03526848Phase 1

3BNC117 and 10-1074 in ART-treated Individuals

Completed
NCT03041012Phase 2

Early Administration of Romidepsin and 3BNC117 in Treatment-naïve HIV Patients Starting ART

Completed
NCT02850016Phase 2

Romidepsin Plus 3BNC117 Phase 2a Study

Completed
NCT03719664Phase 2

Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects

Unknown
NCT02588586Phase 2

A Study of the Safety and Antiretroviral Activity of 3BNC117

Completed
NCT04819347Phase 2

Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection

Unknown
NCT02446847Phase 2

3BNC117 Monoclonal Antibody in HIV-infected Subjects During Treatment Interruption

Completed
NCT02825797Phase 1

3BNC117 and 10-1074 in HIV-infected Individuals

Completed
NCT02824536Phase 1

3BNC117 and 10-1074 in HIV Uninfected Adults

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9